← Back to patent-cliff list
CAS 17345-61-8
3,4-dihydroxybenzonitrile
Codes: ICOT-018
Application context (from source-drug indications)
Non-small cell lung cancerIcotinib HydrochlorideLung adenocarcinomaIcotinib HydrochlorideBronchial neoplasmIcotinib HydrochlorideLung cancerIcotinib HydrochlorideMetastatic breast cancerIcotinib HydrochloridePsoriasisIcotinib Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Icotinib Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate)→3-ethynylaniline→3,4-dihydroxybenzonitrile→2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→13-nitro-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→13-amino-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecine-12-carbonitrile→(E)-N'-(13-cyano-2,3,5,6,8,9-hexahydrobenzo[b][1,4,7,10]tetraoxacyclododecin-12-yl)-N,N-dimethylformimidamide
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.